7.10
+0.04(+0.57%)
Currency In USD
| Previous Close | 7.06 |
| Open | 6.98 |
| Day High | 7.15 |
| Day Low | 6.93 |
| 52-Week High | 8.85 |
| 52-Week Low | 4.76 |
| Volume | 136,540 |
| Average Volume | 165,520 |
| Market Cap | 265.53M |
| PE | -5.59 |
| EPS | -1.27 |
| Moving Average 50 Days | 7.19 |
| Moving Average 200 Days | 6.86 |
| Change | 0.04 |
If you invested $1000 in Lifecore Biomedical, Inc. (LFCR) since IPO date, it would be worth $571.66 as of October 31, 2025 at a share price of $7.1. Whereas If you bought $1000 worth of Lifecore Biomedical, Inc. (LFCR) shares 4 years ago, it would be worth $736.51 as of October 31, 2025 at a share price of $7.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
GlobeNewswire Inc.
12 hours ago
Webcast Scheduled for Thursday, November 6 at 4:30 p.m. EasternCHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”),
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinic
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
GlobeNewswire Inc.
Oct 28, 2025 11:00 AM GMT
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyP